Author:
Frankel Arthur E.,Kreitman Robert J.,Pastan Ira,Murphy John R.
Reference556 articles.
1. Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF et al. Highly specific tumor binding of a 213Bis-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001; 61: 2804–8.
2. Hellstrom I, Hellstrom KE, Senter PD. Development and activities of the BR96-doxorubicin immunoconjugate. Meth Mol Biol 2001; 166: 3–16.
3. Gottstein C, Wels W, Ober B, Thorpe PE. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. Biotechniques 2001; 30: 190–4.
4. Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997; 197: 444–59.
5. Schrama D, thor Straten P, Fischer WH et al. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14: 111–21.